Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median overall survival compared with standard chemotherapy in pretreated metastatic pancreatic cancer (Abstract LBA5).
Mazyar Shadman, MD, of the University of Washington and Fred Hutchinson Cancer Center, describes the safety and efficacy results of the all-oral first-line combination regimen of sonrotoclax and zanubrutinib for patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as the doublet’s effect on measurable residual disease (Abstract 7043). He also discusses the phase III BGB-11417-304/CELESTIAL-TNCLL-2 trial; this ongoing study is evaluating sonrotoclax plus zanubrutinib vs venetoclax and acalabrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL) (Abstract TPS7099).
Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional therapy in patients with resectable, locally advanced stage III melanoma (Abstract LBA9517).
Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-04 trial. The study compared sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in patients with previously untreated PD-L1–positive metastatic triple-negative breast cancer (Abstract LBA1000).
Elizabeth McDonald, MD, PhD, of the University of Pennsylvania, discusses results from a retrospective cohort study that showed that the use of GLP-1 treatment was associated with a significantly lower incidence of breast cancer, after accounting for age, race, ethnicity, BMI, breast density, and type 2 diabetes status (Abstract 10506).
Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer (Abstract 5515).
